← Eichor
Study identifier: NCT04648462 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

Condition: Astrocytoma · Ependymoma · Ganglioglioma  ·  Sponsor: Maastricht Radiation Oncology

PhaseN/A
Planned participants1500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Ac…

This description comes directly from the study's public registry record.

Talk to the study team

Danielle Eekers  ·  +31884455600  ·  danielle.eekers@maastro.nl

Hiske van der Weide  ·  +31503612711  ·  h.l.van.der.weide@umcg.nl

Always discuss trial participation with your own doctor first.

Locations (3)

Maastricht Radiation OncologyMaastricht, Limburg, NetherlandsRecruiting
Holland PTCDelft, South Holland, NetherlandsRecruiting
Universitair Medisch Centrum GroningenGroningen, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04648462